Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 3/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | DCK | P27707 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25545990 | 0.91 | FBP1 (0.42) | FBP1PTGESAAK1S1PR4PTGS2 | |
| SCHEMBL25545528 | 0.90 | FBP1 (0.43) | FBP1PTGESAAK1S1PR4PTGS2 | |
| SCHEMBL25545988 | 0.89 | FBP1 (0.43) | FBP1PTGESAAK1S1PR4PTGS2 | |
| SCHEMBL25545551 | 0.87 | FBP1 (0.43) | FBP1AAK1S1PR4PTGS2TLR7 | |
| SCHEMBL25545925 | 0.84 | ALDH1A1 (0.42) | FBP1AAK1KMT2APTGS2PTGS1 | |
| SCHEMBL25546019 | 0.82 | FBP1 (0.41) | FBP1KMT2ADCK | |
| SCHEMBL25545566 | 0.82 | FBP1 (0.43) | FBP1DCK | |
| SCHEMBL25546027 | 0.81 | FBP1 (0.43) | FBP1PTGESDCK | |
| SCHEMBL25545547 | 0.80 | AAK1 (0.36) | FBP1PTGESAAK1S1PR4NR1H4 | |
| SCHEMBL25556402 | 0.79 | PTGS1 (0.42) | FBP1AAK1S1PR4KMT2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150997-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | FBP1 735/4885PTGES 4257/4885AAK1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.